Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 8, 2008 - Issue 12
Submit an article Journal homepage
703
Views
14
CrossRef citations to date
0
Altmetric
Editorial

Immune markers for Huntington’s disease?

Edward Wild Department of Neurodegenerative Disease, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3NG, UK. [email protected]
,
Maria Björkqvist Neuronal Survival Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Center, Lund University, Lund, Sweden. [email protected]
&
Sarah J Tabrizi Department of Neurodegenerative Disease, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, Queen Square, London, WC1N 3NG, UK. [email protected]
Pages 1779-1781 | Published online: 09 Jan 2014

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

David Cabañero, Elena Martín-García & Rafael Maldonado. (2021) The CB2 cannabinoid receptor as a therapeutic target in the central nervous system. Expert Opinion on Therapeutic Targets 25:8, pages 659-676.
Read now
Fernando Sánchez-López, Inmaculada Tasset, Eduardo Agüera, Montserrat Feijóo, Ricardo Fernández-Bolaños, Francisco M Sánchez, María C Ruiz, Antonio H Cruz, Félix Gascón & Isaac Túnez. (2012) Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease. Neurological Research 34:7, pages 721-724.
Read now

Articles from other publishers (12)

Sarah Eide, Melissa Misztal & Zhong-Ping Feng. (2023) Interleukin-6 as a marker of Huntington's disease progression: Systematic review and meta-analysis. Brain, Behavior, & Immunity - Health 30, pages 100635.
Crossref
Boru Jin, Guoqiang Fei, Shaoming Sang & Chunjiu Zhong. (2023) Identification of biomarkers differentiating Alzheimer’s disease from other neurodegenerative diseases by integrated bioinformatic analysis and machine-learning strategies. Frontiers in Molecular Neuroscience 16.
Crossref
Ayman E. El-Sahar, Alyasaa A. Rastanawi, Muhammed F. El-Yamany & Muhammed A. Saad. (2020) Dapagliflozin improves behavioral dysfunction of Huntington's disease in rats via inhibiting apoptosis-related glycolysis. Life Sciences 257, pages 118076.
Crossref
Beata Lontay, Andrea Kiss, László Virág & Krisztina Tar. (2020) How Do Post-Translational Modifications Influence the Pathomechanistic Landscape of Huntington’s Disease? A Comprehensive Review. International Journal of Molecular Sciences 21:12, pages 4282.
Crossref
Davina J. Hensman Moss, Nicola Robertson, Ruth Farmer, Rachael I. Scahill, Salman Haider, Michela A. Tessari, Geraldine Flynn, David F. Fischer, Edward J. Wild, Douglas Macdonald & Sarah J. Tabrizi. (2017) Quantification of huntingtin protein species in Huntington’s disease patient leukocytes using optimised electrochemiluminescence immunoassays. PLOS ONE 12:12, pages e0189891.
Crossref
Gillian P. Bates, Ray Dorsey, James F. Gusella, Michael R. Hayden, Chris Kay, Blair R. Leavitt, Martha Nance, Christopher A. Ross, Rachael I. Scahill, Ronald Wetzel, Edward J. Wild & Sarah J. Tabrizi. (2015) Huntington disease. Nature Reviews Disease Primers 1:1.
Crossref
Irina Kerkis, Monica Santoro Haddad, Cristiane Wenceslau Valverde & Sabina Glosman. (2015) Neural and mesenchymal stem cells in animal models of Huntington’s disease: past experiences and future challenges. Stem Cell Research & Therapy 6:1.
Crossref
Christopher A. Ross, Elizabeth H. Aylward, Edward J. Wild, Douglas R. Langbehn, Jeffrey D. Long, John H. Warner, Rachael I. Scahill, Blair R. Leavitt, Julie C. Stout, Jane S. Paulsen, Ralf Reilmann, Paul G. Unschuld, Alice Wexler, Russell L. Margolis & Sarah J. Tabrizi. (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nature Reviews Neurology 10:4, pages 204-216.
Crossref
Maciej Ciesla, Klaudia Skrzypek, Magdalena Kozakowska, Agnieszka Loboda, Alicja Jozkowicz & Jozef Dulak. (2011) MicroRNAs as biomarkers of disease onset. Analytical and Bioanalytical Chemistry 401:7, pages 2051-2061.
Crossref
David W Weir, Aaron Sturrock & Blair R Leavitt. (2011) Development of biomarkers for Huntington's disease. The Lancet Neurology 10:6, pages 573-590.
Crossref
S M Metcalfe. (2011) LIF in the regulation of T-cell fate and as a potential therapeutic. Genes & Immunity 12:3, pages 157-168.
Crossref
Aaron SturrockBlair R. Leavitt. (2010) The Clinical and Genetic Features of Huntington Disease. Journal of Geriatric Psychiatry and Neurology 23:4, pages 243-259.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.